United Therapeutics will present four oral and four poster presentations at the European Society of Cardiology Congress 2026, 28-31 August in Munich, and at the European Respiratory Society Congress 2026, 5-9 September in Barcelona.
Late-breaking analyses from the phase 3 ADVANCE OUTCOMES study indicate ralinepag achieved clinical improvement in a lower-risk pulmonary arterial hypertension population and reduced clinical worsening in PAH patients with connective tissue disease, according to the company.
Analyses from the phase 3 TETON program show nebulized treprostinil improved lung function, demonstrated a consistent benefit in reducing serious clinical worsening events, and showed a dose-dependent magnitude of benefit versus placebo in idiopathic pulmonary fibrosis patients.
Additional presentations feature interim ARTISAN data on parenteral treprostinil and preliminary PHINDER findings on screening for pulmonary hypertension associated with interstitial lung disease.
In June 2026, the company submitted a New Drug Application for ralinepag and a supplemental New Drug Application for nebulized treprostinil to the U.S. Food and Drug Administration; both agents remain investigational.
